4.2. Safety
flatulence, GI bleeding, constipation, pain, dizziness, naupathia, vomiting, pruritus, headache
EVENTS, GI BLEEDING
Although IVIB may avoid sensitization of pain receptors by inhibiting the inflammatory cascade response resulting from invasive procedures, there is some safety issues associated with the use of NSAIDs. In the data of this study, GI bleeding and renal events, regarded as acute safety profile, occurred in only one case in the IVIB 400 mg group. Importantly, the occurrence of common AEs, including naupathia, vomiting, constipation, headache, flatulence, pruritus, and dizziness, caused almost no meaningful safety problems, compared to placebo. There was evidence of an elevated risk when IVIB is infused for more than 5 days, or a high-risk group, owing in part to its selectivity for the cyclooxygenase-1 (COX1) enzyme [